Search research articles
Contact Us
Filters
Showing results (31-40 of 60) with videos related to
Page
of 6
Sort By:
ESMO Open
|
December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancer
S M Tolaney, N Tung, A C Wolff, et al.
ESMO Open
|
January 20, 2026
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data
S M Tolaney, S Sammons, A Sandoval-Leon, et al.
ESMO Open
|
March 5, 2026
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
D Trapani, S K Deshmukh, T Samec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
K Kalinsky, J R Diamond, L T Vahdat, et al.
ESMO Open
|
June 8, 2026
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer
E Salehi, X Chu, E L Mayer, et al.
ESMO Open
|
January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2
X Qiu, P Tarantino, R Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
R Barroso-Sousa, W T Barry, H Guo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
E L Mayer, D Trapani, S-E Kim, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 60) with videos related to
Sort By:
Page
of 6
ESMO Open
|
December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancer
S M Tolaney, N Tung, A C Wolff, et al.
ESMO Open
|
January 20, 2026
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data
S M Tolaney, S Sammons, A Sandoval-Leon, et al.
ESMO Open
|
March 5, 2026
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
D Trapani, S K Deshmukh, T Samec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
K Kalinsky, J R Diamond, L T Vahdat, et al.
ESMO Open
|
June 8, 2026
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer
E Salehi, X Chu, E L Mayer, et al.
ESMO Open
|
January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2
X Qiu, P Tarantino, R Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
R Barroso-Sousa, W T Barry, H Guo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
E L Mayer, D Trapani, S-E Kim, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Page
of 6